Session Content References

This session is meant to address the initial steps required for building a radiopharmaceutical program. Crucial to starting a program is understanding the business case, which includes understanding the potential referral stream, reimbursement, personnel, space, and equipment costs to start a program. Then, we will hear from speakers specifically regarding the space, radioactive materials license, and protocol requirements for starting a program. Finally, we will hear about the clinic and staffing needs to start a program. We will seek to educate using experienced professionals from freestanding centers, hospitals, and consulting organizations.

Program Objectives
Upon completion of this live activity, attendees should be able to do the following:

1. Understand the business case for starting a radiopharmaceutical therapy program.
2. Know the basic space and regulatory requirements for radiopharmaceutical therapy.
3. Appreciate the personnel and clinical process needs to deliver a radiopharmaceutical program.

This session will explore two essential components of a successful RPT program: authorized user credentialing process and structured training for medical physicists. It will include a step-by-step overview of the regulatory pathway for obtaining AU status, including required training and documentation. In addition, clinical training experiences for medical physicist to support RPT will be shared.

Program Objectives
Upon completion of this live activity, attendees should be able to do the following:

1. Outline the regulatory requirements and application process to obtain AU status.
2. Apply strategies to develop or improve institutional training programs.

Session will describe the logistics behind radiopharmaceutical therapy (RPT) administration, starting with drug receipt, preparation, infusion, and finishing with patient release.  The session will also highlight the role of the qualified medical physicist (QMP) in ensuring safety, quality, and regulatory compliance for RPT administration. Format will be a panel of two QMPs from academic and community-hospital settings sharing their experience with regard to RPT administration, procedure development, and training. 

Program Objectives
Upon completion of this live activity, attendees should be able to do the following:

1. Learn about drug preparation.
2. Learn about methods for therapy infusion.
3. Learn about patient release and radiation safety considerations.

Increasing access and addressing unmet needs are critical to the continued growth and adoption of radiopharmaceutical therapy. This session will summarize the current barriers to access and discuss solutions to increase physician and patient access to these important therapies. Major unmet needs will be defined and solutions discussed. Solutions that involve multidisciplinary approaches at academic and community-based centers will be highlighted.

Program Objectives
Upon completion of this live activity, attendees should be able to do the following:

1. Plan and implement solutions to increase access to radiopharmaceutical therapy at your center.
2. Engage and collaborate with colleagues, hospital leadership, cooperative groups, professional societies and industry on solutions needed to address the unmet needs in radiopharmaceutical therapy. 

This session will explore critical operational, clinical and administrative considerations for maturing and optimizing established radiopharmaceutical and theranostics programs. 

Program Objectives
Upon completion of this live activity, attendees should be able to:

1. Identify best practices in revenue cycle management specific to theranostics, including managing prior authorizations and payer communication. 
2. Design effective multidisciplinary coordination pathways between nuclear medicine, oncology, urology, endocrinology, radiology, and referring providers to optimize patient outcomes.    
3. Evaluate and implement workflow optimization strategies, including the use of software tools, inventory tracking systems, and electronic health record (EHR) integration.  
4. Develop and apply continuous audit and quality assessment processes to monitor program success, compliance, and operational improvements. 
5. ecognize emerging considerations such as staffing models, training needs, and patient experience metrics that contribute to long-term program sustainability. 

Program Objectives

Upon completion of this live activity, attendees should be able to do the following:

1. Understand best practices for collaboration.
2. Review common institutional hurdles.
3. Develop a path forward for your institution.

While most oncologists are familiar with the development, execution and reporting of interventional clinical trials that improve patient outcomes, there are unique challenges that must be considered when evaluating radioactive drugs. These encompass institutional, radiation safety, budgetary, cooperative group, and regulatory concerns. We will hear three unique perspectives from experts in drug development, regulatory affairs, and clinical investigation.

Program Objectives
Upon completion of this live activity, attendees should be able to do the following:

1. Understand unique challenges that RPT trials pose for investigators, institutions, and patients.
2. Understand regulatory hurdles for the clinical investigation of RPT.   
3. Highlight opportunities for development and implementation of novel therapies with radioactive drugs.

This session will focus on practical clinical challenges in the management of patients receiving radiopharmaceutical therapies (RPT).  Expert speakers will discuss a broad range of common challenges related to radiation safety, renal and hematologic dysfunction, response assessment and decisions about discontinuing or holding treatment.  Specific case examples will complement review of published literature and guidelines.  The audience and speakers will engage in open questions and discussion at the end of the session. 

Program Objectives
Upon completion of this live activity, attendees should be able to do the following:

1. Assess and manage renal and hematologic dysfunction during RPT.
2. Assess and manage patients with complex radiation safety considerations during RPT.
3. Describe potential indications for discontinuing or holding treatment with RPT.

In this session, expert speakers will discuss the future of theranostics. They will pay specific attention to the following topics: novel cancer-specific targets, novel pan-cancer targets, and the potential use of alpha emitters. This will focus on current preclinical work and clinical trials in progress.

Program Objectives
Upon completion of this live activity, attendees should be able to do the following:

1. Identify novel cancer-specific targets for theranostics.
2. Understand the potential of pan-cancer targets in theranostics.
3. Learn the differences between different alpha emitters, and challenges with implementation.

As the interest and use of Radiopharmaceutical Therapy is rapidly growing, so too is the practice of dosimetry. However, the methods and applications vary widely from site to site and often from practitioner to practitioner. We will review the basic methods and tools available for dosimetry as well as the most salient recent results. Our second talk will focus on the efforts towards harmonization of methods and results and development of the tools, QA, phantoms needed to achieve those goals.   

Program Objectives
Upon completion of this live activity, attendees should be able to do the following:

1. How to find software and other tools to perform dosimetry.
2. Be knowledgeable on the basic principles of RPT dosimetry.
3. Identify QA solutions for RPT.

In this session, we will explore some of the basic radiobiologic principles of radiopharmaceutical therapy. Topics that may be addressed include, but are not limited to, relative biological effectiveness (RBE), ranges, linear energy transfer (LET), radionuclide activity, pharmacokinetics, and pharmacodynamics. We will also explore innovative preclinical and translational research with radiopharmaceuticals, including combination therapies to engage an anti-tumor immune response.

Program Objectives
Upon completion of this live activity, attendees should be able to do the following:

1. Understand basic radiobiological principles of various forms of radiopharmaceuticals.
2. Describe novel strategies of pre-clinical to clinical translation in the field of radiopharmaceuticals.  
3. Describe some of the scientific rationale behind novel pairings of radiopharmaceuticals with other systemic agents.